ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
1541
Pozycja w akcjach
#19248
ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily... ImmuneOnco Biopharmaceuticals (Shanghai) Inc. is a biotechnology firm primarily dedicated to advancing immunotherapeutic treatments for various cancers. At the forefront of its development pipeline is IMM01, a CD47-targeting molecule currently undergoing clinical investigation. This lead candidate is being evaluated for its efficacy across a broad spectrum of malignancies, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), classical Hodgkin lymphoma (cHL), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinomas (HNSCC), and colorectal cancer (CRC). Beyond its primary program, the company boasts a robust portfolio of experimental therapies. These comprise IMM0306, a bispecific CD47×CD20 molecule aimed at relapsed/refractory B-cell non-Hodgkin lymphoma (B-NHL); IMM2902, another bispecific agent combining CD47 and HER2 for solid tumors that are either HER2-positive or HER2-low expressing; and IMM2520, a bispecific CD47×PD-L1 molecule intended for various solid tumors. Further development efforts include IMM47, a humanized monoclonal antibody designed to target CD24 for cancer treatment; MM4701, a distinct bispecific molecule simultaneously engaging both CD47 and CD24; IMM2510, a bispecific "mAb-Trap" engineered to block both VEGF and PD-L1; IMM27M, a CTLA-4 antibody enhanced for ADCC activity; and IMM40H, a humanized IgG1 CD70 monoclonal antibody also featuring augmented ADCC activity. The company was established in 2015 and is headquartered in Shanghai, China.
Cena akcji
$0.38122017
Ostatnia synchronizacja: 2026-10-16
Kapitalizacja rynkowa
$159.74M
Zmiana (1 dzień)
2.58%
Zmiana (1 rok)
-71.65%
Kraj
CN
Handel ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (1541)
Kategoria
Healthcare
Kapitalizacja rynkowa ImmuneOnco Biopharmaceuticals (Shanghai) Inc.(1541)
Kapitalizacja rynkowa: $159.74M
Na dzień October 2026 spółka ImmuneOnco Biopharmaceuticals (Shanghai) Inc. ma kapitalizację rynkową wynoszącą $159.74M. Według naszych danych, czyni to ImmuneOnco Biopharmaceuticals (Shanghai) Inc. 19248th najcenniejszą firmą na świecie pod względem kapitalizacji rynkowej. Kapitalizacja rynkowa to całkowita wartość rynkowa wszystkich wyemitowanych akcji spółki giełdowej i jest powszechnie stosowana do oceny jej wartości.
Historia kapitalizacji rynkowej ImmuneOnco Biopharmaceuticals (Shanghai) Inc. od 2023 do 2026
1541 w porównaniu do 5 najpopularniejszych stocks
